Reaching Consensus on the Adoption of Oncology Biosimilars

Learn from expert faculty what key clinical considerations inform the use of biosimilars in oncology practice with this series of ClinicalThought&trade commentaries!

Share

Program Content

Activities

Biosimilars vs Biologics
Insights on Developing and Evaluating Biosimilars for Cancer Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 14, 2018

Expires: November 13, 2019

Biosimilar Integration
Addressing Barriers to Biosimilar Integration in Cancer Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2018

Expires: December 17, 2019

Available Biosimilars
Biosimilar Updates for Supportive and Therapeutic Cancer Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 18, 2019

Expires: January 17, 2020

Faculty

cover img faculity

Jeffrey Crawford, MD

George Barth Geller Professor for Research in Cancer

Duke University Medical Center

Co-director of the Solid Tumor Therapeutics Program

Duke Cancer Institute

Durham, North Carolina

cover img faculity

Gary Lyman, MD, MPH, FASCO, FRCP (Edin)

Co-Director, Hutchinson Institute for Cancer Outcomes Research (HICOR)
Public Health Sciences and Clinical Research Divisions
Fred Hutchinson Cancer Research Center
Professor of Medicine/Medical Oncology
University of Washington School of Medicine
Seattle, Washington

cover img faculity

Rowena N. Schwartz, PharmD, BCOP

Associate Professor
University of Cincinnati
Cincinnati, Ohio

Provided by

ProCE Banner

Supporters

This activity is supported by an educational funding donation provided by

Amgen, Inc.